Prevalence of Antibodies to 2009 Pandemic Influenza A (H1N1) Virus in German Adult Population in Pre- and Post-Pandemic Period

Background In order to detect levels of pre-existing cross-reactive antibodies in different age groups and to measure age-specific infection rates of the influenza A (H1N1) 2009 pandemic in Germany, we conducted a seroprevalence study based on samples from an ongoing nationwide representative health survey. Methodology/Principal Findings We analysed 845 pre-pandemic samples collected between 25 Nov 2008 and 28 Apr 2009 and 757 post-pandemic samples collected between 12 Jan 2010 and 24 Apr 2010. Reactive antibodies against 2009 pandemic influenza A (H1N1) virus (pH1N1) were detected using a haemagglutination inhibition test (antigen A/California/7/2009). Proportions of samples with antibodies at titre ≥40 and geometric mean of the titres (GMT) were calculated and compared among 6 age groups (18–29, 30–39, 40–49, 50–59, 60–69, ≥70 years). The highest proportions of cross-reactive antibodies at titre ≥40 before the pandemic were observed among 18–29 year olds, 12.5% (95% CI 7.3–19.5%). The highest increase in seroprevalence between pre- and post-pandemic was also observed among 18–29 year olds, 29.9% (95% CI 16.7–43.2%). Effects of sampling period (pre- and post-pandemic), age, sex, and prior influenza immunization on titre were investigated with Tobit regression analysis using three birth cohorts (after 1976, between 1957 and 1976, and before 1957). The GMT increased between the pre- and post-pandemic period by a factor of 10.2 (95% CI 5.0–20.7) in the birth cohort born after 1976, 6.3 (95% CI 3.3–11.9) in those born between 1957 and 1976 and 2.4 (95% CI 1.3–4.3) in those born before 1957. Conclusions/Significance We demonstrate that infection rates differed among age groups and that the measured pre-pandemic level of cross-reactive antibodies towards pH1N1 did not add information in relation to protection and prediction of the most affected age groups among adults in the pandemic.

[1]  P. Kamtsiuris,et al.  DEGS: Studie zur Gesundheit Erwachsener in Deutschland , 2012, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[2]  W. Haas,et al.  Epidemiologischer Steckbrief der pandemischen Influenza (H1N1) 2009 basierend auf Einzelfallmeldungen nach Infektionsschutzgesetz , 2010, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[3]  D. Skowronski,et al.  Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic , 2010, Canadian Medical Association Journal.

[4]  Benjamin J Cowling,et al.  The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Q. S. Huang,et al.  Risk Factors and Immunity in a Nationally Representative Population following the 2009 Influenza A(H1N1) Pandemic , 2010, PloS one.

[6]  M. Cretikos,et al.  Influenza A (H1N1) 2009 Antibodies in Residents of New South Wales, Australia, after the First Pandemic Wave in the 2009 Southern Hemisphere Winter , 2010, PloS one.

[7]  K Waalen,et al.  High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[8]  A. Gilsdorf,et al.  The first wave of pandemic influenza (H1N1) 2009 in Germany: From initiation to acceleration , 2010, BMC infectious diseases.

[9]  S. Salmaso,et al.  Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. , 2010, Vaccine.

[10]  James E. Crowe,et al.  Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.

[11]  N. Andrews,et al.  Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study , 2010, The Lancet.

[12]  A. Berger,et al.  Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? , 2010, Medical Microbiology and Immunology.

[13]  L. Kinnunen,et al.  High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  Libo Dong,et al.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.

[15]  Shanta M Zimmer,et al.  Historical perspective--Emergence of influenza A (H1N1) viruses. , 2009, The New England journal of medicine.

[16]  L. Finelli,et al.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans. , 2009, The New England journal of medicine.

[17]  Bjoern Peters,et al.  Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population , 2009, Proceedings of the National Academy of Sciences.

[18]  A. Gilsdorf,et al.  Influenza A(H1N1)v in Germany: the first 10,000 cases. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  A. Heath,et al.  Reproducibility of Serologic Assays for Influenza Virus A (H5N1) , 2009, Emerging infectious diseases.

[20]  Derek Gatherer,et al.  The 2009 H1N1 influenza outbreak in its historical context. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[21]  J. Zarocostas,et al.  World Health Organization declares A (H1N1) influenza pandemic , 2009, BMJ : British Medical Journal.

[22]  O. Pons Bootstrap of means under stratified sampling , 2007, 0709.3246.

[23]  A. Meijer,et al.  Epidemiological and virological assessment of influenza activity in Europe during the winter 2005-2006. , 2007, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[24]  R. G. Das,et al.  Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. , 2007, Vaccine.

[25]  A. Meijer,et al.  Epidemiological and virological assessment of influenza activity in Europe, during the 2006-2007 winter. , 2005 .

[26]  J. Piercy,et al.  Immunogenicity and protective efficacy of influenza vaccination. , 2004, Virus research.

[27]  A. Osterhaus,et al.  Preferential HLA Usage in the Influenza Virus-Specific CTL Response1 , 2004, The Journal of Immunology.

[28]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[29]  Seroepidemiological studies of pandemic influenza A (H1N1) 2009 virus. , 2010, Releve epidemiologique hebdomadaire.

[30]  Anthony W. Mounts,et al.  Update: novel influenza A (H1N1) virus infection - Mexico, March-May, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[31]  Hong Sun,et al.  Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. , 2009 .

[32]  J. Paget,et al.  European Influenza Surveillance Scheme: annual report 2006-2007 influenza season. , 2008 .

[33]  A. Meijer,et al.  Epidemiological and virological assessment of influenza activity in Europe, during the 2004-2005 winter. , 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[34]  A. Meijer,et al.  Epidemiological and virological assessment of influenza activity in Europe during the 2003-2004 season. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[35]  J. Tobin Estimation of Relationships for Limited Dependent Variables , 1958 .